Human Uses


vaccaeThe first practical development and use of immuno-moderating bacteria commenced back in the 1970’s with Mycobacterium-vaccae. This bacterium was initially developed by our lead scientist Professor John Stanford, Emeritus Professor at University College London and M.vaccae is now being used in many parts of the world for a variety of different treatments namely TB, leprosy and cancer. More recently, the development of one of our other bacterium M.obuense is now being put through a Phase II Clinical Trial for the treatment of pancreatic cancer.

Our current initiative is to progress treatments for Type II Diabetes, allergies such as asthma and auto-immunities such as TB.  In the next 12-18 months we propose to initiate the first steps for an acceptance trial for Good Clinical Practice (GCP) under our patents for T.inchonensis . This is being undertaken through a patent licence agreement between ourselves, University College London (Business) plc and the bio-technolgy company ActinoPharma Ltd.